# OnCo record elacestrant (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/elacestrant/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "elacestrant" ;
  schema:name "Elacestrant"@en ;
  schema:description "Elacestrant was the first oral oestrogen-receptor degrader (2023), for ESR1-mutant breast cancer detected by blood test."@en ;
  schema:url <https://onco.cc/drugs/elacestrant/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Elacestrant> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27278069> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Elacestrant> ;
  onco:status "approved" ;
  onco:modality "Oral SERD" ;
  schema:alternateName "Orserdu" ;
  onco:approval "US 2023: ESR1-mutant ER+/HER2- advanced breast cancer after ≥1 endocrine therapy" ;
  onco:related <https://onco.cc/biomarkers/er-status/>, <https://onco.cc/biomarkers/esr1-mutation-ctdna/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:companies <https://onco.cc/companies/menarini/> ;
  onco:trials <https://onco.cc/trials/nct07766018/>, <https://onco.cc/trials/nct05596409/>, <https://onco.cc/trials/nct05563220/>, <https://onco.cc/trials/nct06492616/>, <https://onco.cc/trials/nct05386108/>, <https://onco.cc/trials/nct05573126/> .